[8-K] SUTRO BIOPHARMA, INC. Reports Material Event

Rhea-AI Filing Summary

Sutro Biopharma, Inc. reported that it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on The Nasdaq Global Market. Nasdaq’s Listing Qualifications staff confirmed that, as of December 16, 2025, the closing bid price of Sutro’s common stock had been at least $1.00 per share for 10 consecutive business days and that the company satisfies all other applicable listing criteria. This means the prior listing deficiency has been resolved and the related matter is now closed.

The company had previously been notified on June 20, 2025 that its stock had traded below $1.00 per share for 30 consecutive business days, putting it out of compliance with Nasdaq Listing Rule 5450(a)(1). The new notice confirms that Sutro has successfully corrected this issue and remains listed on The Nasdaq Global Market.

Insights

Equity Markets & Listing Standards Analyst

Sutro has resolved its Nasdaq bid-price deficiency and secured continued listing.

Sutro Biopharma has received confirmation from Nasdaq that it again meets the minimum bid price requirement under Listing Rule 5450(a)(1). The stock closed at or above $1.00 per share for 10 consecutive business days as of December 16, 2025, and the company meets all other criteria for The Nasdaq Global Market. Nasdaq has closed the listing matter, removing the immediate risk of delisting tied to this specific rule.

Earlier, on June 20, 2025, Sutro had been notified that its shares traded below $1.00 for 30 consecutive business days, creating a compliance issue. Resolving that deficiency helps preserve access to a major exchange, which can be important for liquidity and institutional ownership. Future disclosures in company filings will show whether the share price remains in compliance over longer periods.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Understanding 8-K Material Events →

false 0001382101 0001382101 2025-12-17 2025-12-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 17, 2025

SUTRO BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38662		47-0926186
(State or other jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

111 Oyster Point Blvd,

South San Francisco, California, 94080

(Address of principal executive offices) (Zip Code)

(650) 881-6500

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		STRO		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On December 17, 2025, Sutro Biopharma, Inc. (the “Company”) received notice from the Listing Qualifications staff (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5450(a)(1). As of December 16, 2025, the closing bid price of the Company’s common stock had been at least $1.00 per share for 10 consecutive business days, and the Company satisfies all other applicable criteria for continued listing on The Nasdaq Global Market. As a result of this determination, the listing matter is now closed.

As previously disclosed, on June 20, 2025, the Company received notice from the Staff of Nasdaq that, because the closing bid price for the Company’s common stock had fallen below $1.00 per share for 30 consecutive business days, the Company no longer complied with the minimum bid price requirement for continued listing on The Nasdaq Global Market under Nasdaq Listing Rule 5450(a)(1).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Sutro Biopharma, Inc.
Date: December 17, 2025				By:		/s/ Gregory Chow
						Gregory Chow
						Chief Financial Officer